ETFs & MarketsPremiumQuanterix Q2 Revenue Miss Sparks Sector-Wide Guidance Revisions
Quanterix reported a revenue miss for the second quarter of 2026, prompting an immediate downward revision of its forward-looking guidance. This shift in financial outlook for the life sciences firm creates potential volatility for specialized biotech ETFs holding the stock.
Published 2 hours ago
Read more →